UCB (OTCMKTS:UCBJY) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJY)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $139.41, but opened at $131.3295. UCB shares last traded at $131.33, with a volume of 1,070 shares.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Wolfe Research upgraded UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 14th. Three analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Strong Buy”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The company has a 50 day simple moving average of $149.10 and a 200-day simple moving average of $145.70.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.